JP2012522797A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012522797A5 JP2012522797A5 JP2012503704A JP2012503704A JP2012522797A5 JP 2012522797 A5 JP2012522797 A5 JP 2012522797A5 JP 2012503704 A JP2012503704 A JP 2012503704A JP 2012503704 A JP2012503704 A JP 2012503704A JP 2012522797 A5 JP2012522797 A5 JP 2012522797A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- salt
- item
- preparing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 174
- 150000003839 salts Chemical class 0.000 claims description 138
- 238000000034 method Methods 0.000 claims description 93
- 125000006239 protecting group Chemical group 0.000 claims description 21
- 229920006395 saturated elastomer Polymers 0.000 claims description 16
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 14
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 12
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 9
- 125000005842 heteroatom Chemical group 0.000 claims description 8
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 7
- 150000001412 amines Chemical class 0.000 claims description 7
- 239000012022 methylating agents Substances 0.000 claims description 7
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 7
- 239000002168 alkylating agent Substances 0.000 claims description 5
- 229940100198 alkylating agent Drugs 0.000 claims description 5
- 150000002500 ions Chemical class 0.000 claims description 5
- 150000003891 oxalate salts Chemical class 0.000 claims description 5
- LKQAJXTWYDNYHK-VIFPVBQESA-N (2s)-2-benzylaziridine Chemical compound C=1C=CC=CC=1C[C@H]1CN1 LKQAJXTWYDNYHK-VIFPVBQESA-N 0.000 claims description 4
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 4
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 claims description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 3
- 229930195722 L-methionine Natural products 0.000 claims description 3
- 239000003153 chemical reaction reagent Substances 0.000 claims description 3
- 230000008878 coupling Effects 0.000 claims description 3
- 238000010168 coupling process Methods 0.000 claims description 3
- 238000005859 coupling reaction Methods 0.000 claims description 3
- 230000000447 dimerizing effect Effects 0.000 claims description 3
- 229960004452 methionine Drugs 0.000 claims description 3
- 230000003301 hydrolyzing effect Effects 0.000 claims description 2
- 230000001035 methylating effect Effects 0.000 claims 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 42
- 239000002904 solvent Substances 0.000 description 17
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 16
- 239000000203 mixture Substances 0.000 description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 239000000010 aprotic solvent Substances 0.000 description 8
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- 150000001408 amides Chemical class 0.000 description 5
- -1 tert-butylsulfonyl Chemical group 0.000 description 5
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 4
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 4
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 4
- 238000005984 hydrogenation reaction Methods 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 125000005270 trialkylamine group Chemical group 0.000 description 4
- XFNJVJPLKCPIBV-UHFFFAOYSA-N trimethylenediamine Chemical compound NCCCN XFNJVJPLKCPIBV-UHFFFAOYSA-N 0.000 description 4
- CSRZQMIRAZTJOY-UHFFFAOYSA-N trimethylsilyl iodide Chemical group C[Si](C)(C)I CSRZQMIRAZTJOY-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000001476 alcoholic effect Effects 0.000 description 3
- 238000010511 deprotection reaction Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- VHRGRCVQAFMJIZ-UHFFFAOYSA-N cadaverine Chemical compound NCCCCCN VHRGRCVQAFMJIZ-UHFFFAOYSA-N 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 125000004494 ethyl ester group Chemical group 0.000 description 2
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
- ANYSGBYRTLOUPO-UHFFFAOYSA-N lithium tetramethylpiperidide Chemical compound [Li]N1C(C)(C)CCCC1(C)C ANYSGBYRTLOUPO-UHFFFAOYSA-N 0.000 description 2
- 229910052987 metal hydride Inorganic materials 0.000 description 2
- 150000004681 metal hydrides Chemical group 0.000 description 2
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N methyl monoether Natural products COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 230000000269 nucleophilic effect Effects 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 2
- YAXWOADCWUUUNX-UHFFFAOYSA-N 1,2,2,3-tetramethylpiperidine Chemical compound CC1CCCN(C)C1(C)C YAXWOADCWUUUNX-UHFFFAOYSA-N 0.000 description 1
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- ITWBWJFEJCHKSN-UHFFFAOYSA-N 1,4,7-triazonane Chemical compound C1CNCCNCCN1 ITWBWJFEJCHKSN-UHFFFAOYSA-N 0.000 description 1
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 1
- RKMGAJGJIURJSJ-UHFFFAOYSA-N 2,2,6,6-Tetramethylpiperidine Substances CC1(C)CCCC(C)(C)N1 RKMGAJGJIURJSJ-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- RPNUMPOLZDHAAY-UHFFFAOYSA-N Diethylenetriamine Chemical compound NCCNCCN RPNUMPOLZDHAAY-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 239000005700 Putrescine Substances 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- 150000001347 alkyl bromides Chemical group 0.000 description 1
- 150000001348 alkyl chlorides Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 150000001351 alkyl iodides Chemical class 0.000 description 1
- XGIUDIMNNMKGDE-UHFFFAOYSA-N bis(trimethylsilyl)azanide Chemical compound C[Si](C)(C)[N-][Si](C)(C)C XGIUDIMNNMKGDE-UHFFFAOYSA-N 0.000 description 1
- DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 description 1
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 1
- SSJXIUAHEKJCMH-UHFFFAOYSA-N cyclohexane-1,2-diamine Chemical compound NC1CCCCC1N SSJXIUAHEKJCMH-UHFFFAOYSA-N 0.000 description 1
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
- WBJINCZRORDGAQ-UHFFFAOYSA-N ethyl formate Chemical group CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 229910000043 hydrogen iodide Inorganic materials 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- UPRXAOPZPSAYHF-UHFFFAOYSA-N lithium;cyclohexyl(propan-2-yl)azanide Chemical compound CC(C)N([Li])C1CCCCC1 UPRXAOPZPSAYHF-UHFFFAOYSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 1
- NSETWVJZUWGCKE-UHFFFAOYSA-N propylphosphonic acid Chemical compound CCCP(O)(O)=O NSETWVJZUWGCKE-UHFFFAOYSA-N 0.000 description 1
- QBERHIJABFXGRZ-UHFFFAOYSA-M rhodium;triphenylphosphane;chloride Chemical compound [Cl-].[Rh].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 QBERHIJABFXGRZ-UHFFFAOYSA-M 0.000 description 1
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 239000011995 wilkinson's catalyst Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16649809P | 2009-04-03 | 2009-04-03 | |
| US61/166,498 | 2009-04-03 | ||
| PCT/US2010/029633 WO2010115000A2 (en) | 2009-04-03 | 2010-04-01 | Methods and intermediates for preparing pharmaceutical agents |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014104007A Division JP5986599B2 (ja) | 2009-04-03 | 2014-05-20 | チトクロームｐ４５０モノオキシゲナーゼの阻害剤を調製する方法および関わる中間体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012522797A JP2012522797A (ja) | 2012-09-27 |
| JP2012522797A5 true JP2012522797A5 (enExample) | 2013-05-02 |
| JP5612662B2 JP5612662B2 (ja) | 2014-10-22 |
Family
ID=42634770
Family Applications (8)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012503704A Active JP5612662B2 (ja) | 2009-04-03 | 2010-04-01 | チトクロームｐ４５０モノオキシゲナーゼの阻害剤およびそれに関わる中間体 |
| JP2014104007A Active JP5986599B2 (ja) | 2009-04-03 | 2014-05-20 | チトクロームｐ４５０モノオキシゲナーゼの阻害剤を調製する方法および関わる中間体 |
| JP2016014135A Active JP6180561B2 (ja) | 2009-04-03 | 2016-01-28 | チトクロームｐ４５０モノオキシゲナーゼの阻害剤およびそれに関わる中間体 |
| JP2017034914A Active JP6336161B2 (ja) | 2009-04-03 | 2017-02-27 | チトクロームｐ４５０モノオキシゲナーゼの阻害剤およびそれに関わる中間体 |
| JP2017146329A Active JP6491706B2 (ja) | 2009-04-03 | 2017-07-28 | チトクロームｐ４５０モノオキシゲナーゼの阻害剤およびそれに関わる中間体 |
| JP2018115527A Withdrawn JP2018162274A (ja) | 2009-04-03 | 2018-06-18 | チトクロームｐ４５０モノオキシゲナーゼの阻害剤およびそれに関わる中間体 |
| JP2020134426A Withdrawn JP2020189861A (ja) | 2009-04-03 | 2020-08-07 | チトクロームｐ４５０モノオキシゲナーゼの阻害剤およびそれに関わる中間体 |
| JP2022167506A Withdrawn JP2023002679A (ja) | 2009-04-03 | 2022-10-19 | チトクロームｐ４５０モノオキシゲナーゼの阻害剤およびそれに関わる中間体 |
Family Applications After (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014104007A Active JP5986599B2 (ja) | 2009-04-03 | 2014-05-20 | チトクロームｐ４５０モノオキシゲナーゼの阻害剤を調製する方法および関わる中間体 |
| JP2016014135A Active JP6180561B2 (ja) | 2009-04-03 | 2016-01-28 | チトクロームｐ４５０モノオキシゲナーゼの阻害剤およびそれに関わる中間体 |
| JP2017034914A Active JP6336161B2 (ja) | 2009-04-03 | 2017-02-27 | チトクロームｐ４５０モノオキシゲナーゼの阻害剤およびそれに関わる中間体 |
| JP2017146329A Active JP6491706B2 (ja) | 2009-04-03 | 2017-07-28 | チトクロームｐ４５０モノオキシゲナーゼの阻害剤およびそれに関わる中間体 |
| JP2018115527A Withdrawn JP2018162274A (ja) | 2009-04-03 | 2018-06-18 | チトクロームｐ４５０モノオキシゲナーゼの阻害剤およびそれに関わる中間体 |
| JP2020134426A Withdrawn JP2020189861A (ja) | 2009-04-03 | 2020-08-07 | チトクロームｐ４５０モノオキシゲナーゼの阻害剤およびそれに関わる中間体 |
| JP2022167506A Withdrawn JP2023002679A (ja) | 2009-04-03 | 2022-10-19 | チトクロームｐ４５０モノオキシゲナーゼの阻害剤およびそれに関わる中間体 |
Country Status (27)
| Country | Link |
|---|---|
| US (4) | US8497396B2 (enExample) |
| EP (2) | EP2414325B1 (enExample) |
| JP (8) | JP5612662B2 (enExample) |
| KR (3) | KR101728375B1 (enExample) |
| CN (4) | CN107382997B (enExample) |
| AP (1) | AP2887A (enExample) |
| AR (1) | AR076027A1 (enExample) |
| AU (1) | AU2010232559B2 (enExample) |
| BR (1) | BRPI1012638B8 (enExample) |
| CA (4) | CA3008903C (enExample) |
| CL (1) | CL2011002370A1 (enExample) |
| CO (1) | CO6400216A2 (enExample) |
| EA (2) | EA022739B1 (enExample) |
| EC (1) | ECSP11011391A (enExample) |
| ES (1) | ES2548252T3 (enExample) |
| HK (1) | HK1223912A1 (enExample) |
| IL (4) | IL215399A (enExample) |
| MX (2) | MX338731B (enExample) |
| NZ (4) | NZ708978A (enExample) |
| PE (1) | PE20120617A1 (enExample) |
| PT (1) | PT2414325E (enExample) |
| SG (2) | SG10201404926UA (enExample) |
| TW (2) | TW201518283A (enExample) |
| UA (1) | UA108738C2 (enExample) |
| UY (1) | UY32535A (enExample) |
| WO (1) | WO2010115000A2 (enExample) |
| ZA (1) | ZA201107430B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA108738C2 (uk) | 2009-04-03 | 2015-06-10 | Спосіб одержання інгібітора цитохром р450 монооксигенази та залучені проміжні сполуки | |
| JP2012140390A (ja) * | 2011-01-06 | 2012-07-26 | Sumitomo Chemical Co Ltd | α−アミノ−γ−ブチロラクトンの製造方法 |
| US20140187771A1 (en) * | 2011-05-02 | 2014-07-03 | Gilead Sciences, Inc. | Amorphous solid salts |
| RU2014129937A (ru) | 2012-02-03 | 2016-03-27 | Джилид Сайэнс, Инк. | Способы и промежуточные соединения для получения фармацевтических агентов |
| WO2014047849A1 (zh) * | 2012-09-27 | 2014-04-03 | 上海迪赛诺化学制药有限公司 | 细胞色素p450单加氧酶抑制剂中间体及其制法和用途 |
| CN103694196A (zh) * | 2012-09-27 | 2014-04-02 | 上海迪赛诺化学制药有限公司 | 细胞色素p450单加氧酶抑制剂中间体及其制法和用途 |
| WO2014057498A2 (en) | 2012-10-08 | 2014-04-17 | Mylan Laboratories Ltd. | Process for the preparation of cobicistat intermediates |
| WO2014105777A1 (en) * | 2012-12-26 | 2014-07-03 | Assia Chemical Industries Ltd. | Cobicostat dichlohydrate salt |
| CN104370777A (zh) * | 2013-08-13 | 2015-02-25 | 上海迪赛诺化学制药有限公司 | 合成(2r,5r)-1,6-二苯基己烷-2,5-二胺及其盐的中间体及所述中间体的制备方法和应用 |
| CA2931971A1 (en) * | 2013-11-29 | 2015-06-04 | Mylan Laboratories Ltd. | Amorphous cobicistat solid dispersion |
| WO2015083066A1 (en) | 2013-12-03 | 2015-06-11 | Mylan Laboratories Ltd. | Preparation of cobicistat intermediates |
| CN104193643B (zh) * | 2014-09-12 | 2016-02-10 | 宁波九胜创新医药科技有限公司 | 用于合成抗艾滋病药物增强剂cobicistat的中间体 |
| CN104447472A (zh) * | 2014-11-06 | 2015-03-25 | 江苏森萱医药化工股份有限公司 | D)-2-苄基-n,n-二甲基氮杂环丙烷基-1-磺酰胺合成方法 |
| CN104557565B (zh) * | 2015-01-08 | 2016-07-06 | 浙江工业大学 | 抗艾滋病药物增强剂Cobicistat关键中间体盐酸盐的制备方法 |
| WO2016128885A1 (en) * | 2015-02-09 | 2016-08-18 | Laurus Labs Private Limited | A process for preparation of cobicistat |
| EP3259267A4 (en) * | 2015-02-18 | 2019-01-23 | MSN Laboratories Private Limited | A NOVEL PROCESS FOR THE PREPARATION OF 1,3-THIAZOL-5-YLMETHYL [(2R, 5R) -5 - {[(2S) -2 - [(METHYL {[2- (PROPAN-2-YL) -1) CARBAMATE 3-thiazol-4-yl] methyl} carbamoyl) amino] -4- (morpholin-4-yl) butanoyl] amino} -1,6-DIPHÉNYLHEXAN-2-YL] |
| CN107674039A (zh) * | 2016-08-01 | 2018-02-09 | 上海朴颐化学科技有限公司 | 一种可比西他中间体的制备方法 |
| US20180085387A1 (en) | 2016-09-27 | 2018-03-29 | Gilead Sciences, Inc. | Therapeutic compositions for treatment of human immunodeficiency virus |
| CN109912530A (zh) * | 2017-12-13 | 2019-06-21 | 上海奥博生物医药技术有限公司 | 一种可比司他原料杂质的制备方法 |
| CN109232301B (zh) * | 2018-10-15 | 2021-01-01 | 天津希恩思生化科技有限公司 | 一种四异丙基肼的制备方法 |
| CN110642721B (zh) * | 2018-12-21 | 2022-09-30 | 安徽贝克生物制药有限公司 | 盐酸司来吉兰的制备方法 |
| CN110878071A (zh) * | 2019-11-21 | 2020-03-13 | 华南农业大学 | 一种α-氨基-γ-丁内酯及其盐的制备方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1733725T2 (sl) * | 1999-06-04 | 2012-10-30 | Abbott Lab | Farmacevtske formulacije, vsebujoče vsaj eno spojino za inhibicijo HIV proteaze |
| US20030153771A1 (en) | 2001-09-27 | 2003-08-14 | Kolb Hartmuth C. | Large scale synthesis of optically pure aziridines |
| WO2003106445A1 (en) * | 2002-06-12 | 2003-12-24 | Qsi Pharma A/S | Compounds and methods for controlling bacterial virulence |
| MX2007000884A (es) * | 2004-07-23 | 2007-03-12 | Procter & Gamble | Composicion detergente liquida para una limpieza mejorada de la grasa y de la suciedad del almidon a baja temperatura. |
| US7786153B2 (en) * | 2005-03-02 | 2010-08-31 | Abbott Laboratories Inc. | Compounds that are useful for improving pharmacokinetics |
| EA025845B1 (ru) * | 2006-07-07 | 2017-02-28 | Джилид Сайэнс, Инк. | Модуляторы фармакокинетических свойств лекарственных средств |
| EA019893B1 (ru) * | 2007-02-23 | 2014-07-30 | Джилид Сайэнс, Инк. | Фармацевтическая композиция и способ лечения вич-инфекции |
| CN101796040A (zh) * | 2007-07-06 | 2010-08-04 | 吉里德科学公司 | 治疗剂的药代动力学特性调节剂 |
| PT2231628E (pt) * | 2008-01-04 | 2015-12-29 | Gilead Sciences Inc | Inibidores de citocromo p450 |
| EP3006032A1 (en) | 2008-05-02 | 2016-04-13 | Gilead Sciences, Inc. | The use of solid carrier particles to improve the processability of a pharmaceutical agent |
| UA108738C2 (uk) | 2009-04-03 | 2015-06-10 | Спосіб одержання інгібітора цитохром р450 монооксигенази та залучені проміжні сполуки |
-
2010
- 2010-01-04 UA UAA201111540A patent/UA108738C2/ru unknown
- 2010-03-31 AR ARP100101077 patent/AR076027A1/es unknown
- 2010-03-31 TW TW103133537A patent/TW201518283A/zh unknown
- 2010-03-31 TW TW99109929A patent/TWI464165B/zh active
- 2010-04-01 CN CN201710518109.8A patent/CN107382997B/zh active Active
- 2010-04-01 ES ES10713075.9T patent/ES2548252T3/es active Active
- 2010-04-01 US US12/752,639 patent/US8497396B2/en active Active
- 2010-04-01 EA EA201190179A patent/EA022739B1/ru unknown
- 2010-04-01 CN CN201510160505.9A patent/CN104876888B/zh active Active
- 2010-04-01 JP JP2012503704A patent/JP5612662B2/ja active Active
- 2010-04-01 KR KR1020117026120A patent/KR101728375B1/ko active Active
- 2010-04-01 AP AP2011005864A patent/AP2887A/xx active
- 2010-04-01 CN CN202010112624.8A patent/CN111217808A/zh active Pending
- 2010-04-01 EP EP10713075.9A patent/EP2414325B1/en active Active
- 2010-04-01 BR BRPI1012638A patent/BRPI1012638B8/pt active IP Right Grant
- 2010-04-01 CA CA3008903A patent/CA3008903C/en active Active
- 2010-04-01 MX MX2013003678A patent/MX338731B/es unknown
- 2010-04-01 SG SG10201404926UA patent/SG10201404926UA/en unknown
- 2010-04-01 CN CN201080014307.7A patent/CN102438982B/zh active Active
- 2010-04-01 NZ NZ708978A patent/NZ708978A/en unknown
- 2010-04-01 NZ NZ726536A patent/NZ726536A/en unknown
- 2010-04-01 EA EA201590979A patent/EA201590979A1/ru unknown
- 2010-04-01 MX MX2011010397A patent/MX2011010397A/es active IP Right Grant
- 2010-04-01 CA CA3083433A patent/CA3083433C/en active Active
- 2010-04-01 CA CA2925137A patent/CA2925137C/en active Active
- 2010-04-01 SG SG2011069937A patent/SG174585A1/en unknown
- 2010-04-01 NZ NZ617773A patent/NZ617773A/en unknown
- 2010-04-01 AU AU2010232559A patent/AU2010232559B2/en active Active
- 2010-04-01 PE PE2011001737A patent/PE20120617A1/es active IP Right Grant
- 2010-04-01 KR KR1020177009970A patent/KR101874557B1/ko active Active
- 2010-04-01 KR KR1020187018487A patent/KR20180077324A/ko not_active Ceased
- 2010-04-01 NZ NZ59486410A patent/NZ594864A/en unknown
- 2010-04-01 EP EP15171216.3A patent/EP3009434A1/en not_active Withdrawn
- 2010-04-01 PT PT107130759T patent/PT2414325E/pt unknown
- 2010-04-01 WO PCT/US2010/029633 patent/WO2010115000A2/en not_active Ceased
- 2010-04-01 CA CA2754698A patent/CA2754698C/en active Active
- 2010-04-05 UY UY32535A patent/UY32535A/es not_active Application Discontinuation
-
2011
- 2011-09-06 CO CO11114749A patent/CO6400216A2/es not_active Application Discontinuation
- 2011-09-26 CL CL2011002370A patent/CL2011002370A1/es unknown
- 2011-09-27 IL IL215399A patent/IL215399A/en active IP Right Grant
- 2011-10-11 ZA ZA2011/07430A patent/ZA201107430B/en unknown
- 2011-10-12 EC ECSP11011391 patent/ECSP11011391A/es unknown
-
2013
- 2013-06-24 US US13/925,302 patent/US8853210B2/en active Active
-
2014
- 2014-05-20 JP JP2014104007A patent/JP5986599B2/ja active Active
- 2014-09-03 US US14/476,622 patent/US9115100B2/en active Active
-
2015
- 2015-03-10 IL IL237643A patent/IL237643A/en active IP Right Grant
- 2015-03-10 IL IL237642A patent/IL237642A/en active IP Right Grant
- 2015-07-14 US US14/799,090 patent/US9428473B2/en active Active
-
2016
- 2016-01-28 JP JP2016014135A patent/JP6180561B2/ja active Active
- 2016-09-09 HK HK16110713.7A patent/HK1223912A1/en unknown
-
2017
- 2017-01-11 IL IL250068A patent/IL250068A0/en unknown
- 2017-02-27 JP JP2017034914A patent/JP6336161B2/ja active Active
- 2017-07-28 JP JP2017146329A patent/JP6491706B2/ja active Active
-
2018
- 2018-06-18 JP JP2018115527A patent/JP2018162274A/ja not_active Withdrawn
-
2020
- 2020-08-07 JP JP2020134426A patent/JP2020189861A/ja not_active Withdrawn
-
2022
- 2022-10-19 JP JP2022167506A patent/JP2023002679A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012522797A5 (enExample) | ||
| JP6336161B2 (ja) | チトクロームｐ４５０モノオキシゲナーゼの阻害剤およびそれに関わる中間体 | |
| CN103249711B (zh) | 制备2-甲氧基甲基-1,4-苯二胺、其衍生物及其盐的方法 | |
| RU2012122367A (ru) | Способ получения простагландинов и промежуточные соединения для их получения | |
| RU2015111635A (ru) | Улучшенные способы ацилирования майтанзинола | |
| CN110545911A (zh) | 用于由d2制备氘代乙醇的方法 | |
| WO2011098963A1 (en) | Process for the preparation of bortezomib | |
| JP2019515906A5 (enExample) | ||
| RU2006134623A (ru) | Способы получения ингибиторов триптазы | |
| EP2917192A2 (en) | Process for the preparation of cabazitaxel and its intermediates | |
| JP2011506323A5 (enExample) | ||
| JP2013518093A5 (enExample) | ||
| JPWO2022259222A5 (enExample) | ||
| Sagirova et al. | Hydrogenolysis of the CO bond of hydroxylactams as a convenient method for the synthesis of substituted isoindolin-1-ones | |
| CN103421037B (zh) | 1-乙氧羰基-5-甲基-(3r)-叔丁基二甲硅氧基戊二酸酯的合成工艺 | |
| JP2009541305A5 (enExample) | ||
| RU2007134454A (ru) | Способ получения докетаксела | |
| JP2010235585A (ja) | フルオレノンイミンを用いた炭素−炭素結合生成反応 | |
| JP2008512451A5 (enExample) | ||
| HK40022057A (en) | Method and intermediates for preparing pharmaceutical agents | |
| HK1166976B (en) | Method of preparing an inhibitor of cytochrome p450 monooxygenase, and intermediates involved |